DOCSLIB.ORG

Of the Epidemic G2 Rotavirus Strains Over a 25- Year Period (1984-2009) at Dr George Mukhari Hospital

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Of the Epidemic G2 Rotavirus Strains Over a 25- Year Period (1984-2009) at Dr George Mukhari Hospital SEQUENCE ANALYSIS OF VP7 (GENOME SEGMENT 9) OF THE EPIDEMIC G2 ROTAVIRUS STRAINS OVER A 25- YEAR PERIOD (1984-2009) AT DR GEORGE MUKHARI HOSPITAL BY Lekgolo Lorens MAAKE 2012 i SEQUENCE ANALYSIS OF VP7 (GENOME SEGMENT 9) OF THE EPIDEMIC G2 ROTAVIRUS STRAINS OVER A 25- YEAR PERIOD (1984-2009) AT DR GEORGE MUKHARI HOSPITAL By Lekgolo Lorens MAAKE A dissertation in fulfilment of the requirements for the degree of MSc Med (Medical Virology) Submitted In the Department of Virology School of Pathology and Pre-clinical Sciences University of Limpopo (Medunsa Campus) Supervisor Dr Mapaseka L. SEHERI; PhD University of Limpopo (Medunsa Campus) Co-supervisor Dr Selokela G. SELABE; PhD University of Limpopo (Medunsa Campus) i DECLARATION I, Lekgolo Lorens MAAKE, hereby declare that the work presented in this dissertation is original and does not incorporate any material previously submitted for purpose of degree to any other institution. This dissertation is being submitted in fulfilment for the requirements of the degree of Master of Medical Science (Medical Virology), in the Department of Virology, School of Pathology and Pre-Clinical Sciences, Faculty of Health Sciences, at the Medunsa Campus of the University of Limpopo. Works of other investigators where cited and have been duly acknowledged. Signature of student Date i DEDICATION I dedicate this dissertation to my parents Joas and Betty Maake who raised me this far, my brother Sunnyboy Maake who frequently supported me financially, my three sisters, Julia, Ruth and Refentshe whom I always miss, and finally my talkative young brother Petro. ii ACKNOWLEDGEMENTS I would like to thank the almighty God who gave me life, strength and potential to do this study. I would also wish to convey my sincere gratitude to several people and organizations for their support, motivation, advice, comments, criticisms and contributions towards the development of this study. In particular, I would like to thank: Dr LM Seheri for being a superb supervisor, sacrificing her time and for her dedication, willingness and editorial support. Dr SG Selabe for editorial support, motivation and inspiration. Mrs Ina Peenze for SOPs, QLPs, technical support, inspiration and motivation The secretaries in the Department of Virology who always updated me about all the activities and programmes of the department. Prof MJ Mphahlele for all the support, motivation, courage, inspiration and skills that he gave me throughout this project. It is nice to learn from you Prof, more especially the loyalty, tireless efforts and editorial part. Mr Nare Rakgole and Mr Harry Ngobeni for technical support and assistance in analysis of the results. Mr Martin Nyaga for being an academic friend and for training in laboratory techniques. Mrs Gugu Maphalala, Miss Leah Nemarude, Miss Lufuno Netshifhefhe and Miss Relebogile Mapuroma for their inspiration and motivation. Mr Muxe Muzeze, Miss Tsakane Sondlane, Miss Rudzani Malabi, and Miss Tebogo Seleise who have being my true friends from undergraduate degree. The MRC-DPRU and the HHRU staff members at large. Finally I would like to thank the National Research Foundation and the Poliomyelitis Research Foundation for financial assistance. iii TABLE OF CONTENTS DECLARATION...................................................................................................................... I DEDICATION......................................................................................................................... II ACKNOWLEDGEMENTS ................................................................................................. III TABLE OF CONTENTS ..................................................................................................... IV ABSTRACT ........................................................................................................................ VIII LIST OF ABBREVIATIONS .............................................................................................. XI LIST OF NUCLEOTIDES ................................................................................................ XIX LIST OF AMINO ACIDS ................................................................................................... XX LIST OF TABLES ............................................................................................................. XXI LIST OF FIGURES .......................................................................................................... XXII CHAPTER 1: EXPERIMENTAL PROPOSAL ................................................................... 1 1.1 Study problem .................................................................................................................... 1 1.2 Aim ...................................................................................................................................... 2 1.3 Objectives............................................................................................................................ 2 Primary objective ................................................................................................................... 2 Secondary objectives ............................................................................................................. 2 1.4 Expected significance of the study .................................................................................... 3 CHAPTER 2: LITERATURE REVIEW .............................................................................. 4 2.1 Introduction ........................................................................................................................ 4 2.2 History ................................................................................................................................. 4 2.3 Virology and classification ................................................................................................ 5 2.4 Diversity of rotaviruses.................................................................................................... 10 2.4.1 Point mutations ........................................................................................................... 10 2.4.2 Reassortment ............................................................................................................... 11 2.4.3 Rearrangement ............................................................................................................ 11 2.4.4 Interspecies transmission ............................................................................................ 12 2.5 Prevalence of rotavirus genotypes .................................................................................. 13 2.6 Prevalence of G2 worldwide ........................................................................................... 14 2.7 Viral proteins .................................................................................................................... 16 2.7.1 Structural proteins ....................................................................................................... 16 iv 2.7.2 Non-structural proteins ............................................................................................... 19 2.8 Transmission .................................................................................................................... 23 2.9 Pathogenesis...................................................................................................................... 24 2.10 Replication ...................................................................................................................... 27 2.11 Signs and symptoms ....................................................................................................... 28 2.12 Epidemiology .................................................................................................................. 29 2.13 Rotavirus Seasonality .................................................................................................... 30 2.14 Diagnosis ......................................................................................................................... 30 2.15 Therapy and prognosis .................................................................................................. 31 2.16 Immunity ........................................................................................................................ 32 2.17 Vaccines .......................................................................................................................... 33 CHAPTER 3: MATERIALS AND METHODS ................................................................. 36 3.1 Ethical Consideration ...................................................................................................... 36 3.2 Study Site .......................................................................................................................... 36 3.3 Study design ...................................................................................................................... 36 3.4 Sampling and Study population ..................................................................................... 37 3.5 Laboratory Methods ........................................................................................................ 39 3.5.1 Extraction of dsRNA from stool for PAGE ................................................................ 39 3.5.2 Polyacrylamide gel electrophoresis (PAGE) .............................................................
Load more

Recommended publications
  • SUPPLEMENT Collected Recommendations of the Public Health Service Advisory Committee on Immunization Practices
    SUPPLEMENT Collected Recommendations of the Public Health Service Advisory Committee on Immunization Practices The Public Health Service Advisory Committee on The Committee has reviewed all of its statements Immunization Practices has in the last 5 years made within the past several months. Only minor revisions and recommendations concerning the use of vaccines and editorial changes were made. No substantive modifica­ other biologies in the prevention of 16 diseases. Each tions resulted from this annual review. Each of the state­ statement by the AC IP is regularly published in the ments carries the dates of original publication and past Morbidity and Mortality Weekly Report upon com­ revisions. pletion or revision. For the first time, a brief list of selected references is The full series of recommendations has never been appended to each statement. These bibliographies are printed as a single document. However, it was felt that a not meant to be definitive, but are a starting point for supplement to the MMWR incorporating all of the exis­ more extensive review of the pertinent literature on the ting ACIP recommendations would be a useful reference. disease, the vaccine, and its appropriate uses. CONTENTS Page 3 - Cholera Vaccine 4 - Diphtheria and Tetanus Toxoids and Pertussis Vaccine 6 - Immune Serum Globulin for Prevention of Viral Hepatitis 9 - Influenza Vaccine-1969-70 10 - Measles Vaccines 12 - Mumps Vaccine 14 - Plague Vaccine 15 - Poliomyelitis Vaccines 17 - Rabies P rophylaxis 21 - Rubella Virus Vaccine Prelicensing Statement 23 - Smallpox Vaccine 26 - Typhoid Vaccine 27 - Typhus Vaccine 28 - Yellow Fever Vaccine PUBLIC HEALTH SERVICE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES Since its establishment in 1964, the Public Health ences in emphasis have not been felt to compromise the Service Advisory Committee on Immunization Practices goal of achieving immunity in vaccinees.
    [Show full text]
  • Effectiveness of a Monovalent Human Rotavirus Vaccine Among Children of 5 Years and Under in Kwazulu-Natal Osaretin Emmanuel
    EFFECTIVENESS OF A MONOVALENT HUMAN ROTAVIRUS VACCINE AMONG CHILDREN OF 5 YEARS AND UNDER IN KWAZULU-NATAL OSARETIN EMMANUEL ASOWATA SUBMITTED IN FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (MEDICAL MICROBIOLOGY) IN THE SCHOOL OF LABORATORY MEDICINE AND MEDICAL SCIENCES, UNIVERSITY OF KWAZULU-NATAL, SOUTH AFRICA FEBRUARY, 2016 i PREFACE Diarrhoeal disease is one of the leading cause of morbidity and mortality among children of 5 years and under in South Africa. Rotaviruses have been documented as causing one-third of all diarrhoea hospital admissions. Vaccination is the main public health intervention to prevent and control rotavirus infections. Two oral live-attenuated rotavirus vaccines has been has been licensed for global use and one of these vaccines has been included in the national immunization programme of South Africa since August 2009. However, rotavirus remains a major aetiology of diarrhoea in infants and young children in South Africa. Clinical trials in South Africa have reported a low effectiveness of this vaccine in comparison to that reported from high income countries. Reasons for the reduced effectiveness of the rotavirus vaccine seen locally are speculative. The ability of this vaccine to protect against emerging strains of rotavirus is not fully understood. This study was conducted to evaluate possible factors influencing the effectiveness of the rotavirus vaccine on Kwazulu-Natal, South Africa. ii DECLARATION This work was carried out by me, Osaretin Emmanuel Asowata. It has not been submitted in any form to the University of KwaZulu-Natal or any other tertiary institution for degree award purposes. All experiments was carried out in the department of Infection Prevention and Control, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal under the supervision of Professor Prashini Moodley and co-supervised by Dr.
    [Show full text]
  • Nursing and the Development of Neonatal Intensive Care Units in the United States, 1955-1982
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2015 "We Were the Eyes and Ears...": Nursing and the Development of Neonatal intensive Care Units in the United States, 1955-1982. Briana Ralston University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the History Commons, and the Nursing Commons Recommended Citation Ralston, Briana, ""We Were the Eyes and Ears...": Nursing and the Development of Neonatal intensive Care Units in the United States, 1955-1982." (2015). Publicly Accessible Penn Dissertations. 1122. https://repository.upenn.edu/edissertations/1122 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1122 For more information, please contact [email protected]. "We Were the Eyes and Ears...": Nursing and the Development of Neonatal intensive Care Units in the United States, 1955-1982. Abstract ABSTRACT "WE WERE THE EYES AND EARS...": NURSING AND THE DEVELOPMENT OF NEONATAL INTENSIVE CARE UNITS IN THE UNITED STATES, 1955-1982. Briana Ralston, MS, RN Julie Fairman, PhD, RN, FAAN In the 1960s and 1970s, neonatal intensive care units (NICUs) became the standard of care for critically ill newborns in hospitals across the United States. Though work has been done to examine how nurses participated in the development of ICU's for adult populations, scholarship related to the formation of NICUs is sparse. Using historical methodology to examine hospital archival data, oral history interviews, and scholarly literature, this work examines the roles nurses played in the development of NICUs as technological systems between 1955 and 1982 in the United States.
    [Show full text]
  • INT 22 Mount Sinai Archives Interview with Horace L. Hodes, MD by Albert S
    INT 22 Mount Sinai Archives Interview with Horace L. Hodes, MD by Albert S. Lyons, MD October 9, 1974 LYONS: This is October 9, 1974. I’m now interviewing Dr. Horace Hodes in his office in the Annenberg Building on the 17th floor. Horace, when did you first come to Mount Sinai? HODES: I came here on July 1, 1949. I’d never been in this hospital up until about two months before that date. The way I happened to come here was the following. Dr. [Edwards A.] Park, who was my professor at Johns Hopkins and a very wonderful man, had met George Baehr [Director of the 1st Medical Service at The Mount Sinai Hospital] somewhere at a high level meeting. They were both engaged in trying to engineer big changes in medical care in the United States. They were both, as you know, public- spirited people. And at this meeting it transpired that George Baehr was on a search committee looking for a replacement for Murray Bass [Director of Pediatrics, 1942-48] in the Department of Pediatrics. He told Dr. Park that they had decided at Mount Sinai to have a full-time head of the Department of Pediatrics. And in fact, this was the first really completely full-time clinical department the hospital was going to have. [M. Ralph Kaufman, MD, Chief of Psychiatry was the first full-time director of a Mount Sinai service. Ed. ] Dr. Park lived in New York for a short time; he went to Columbia Medical School and had actually started into practice.
    [Show full text]
  • Philadelphia, PA April 28-May 1, 2011
    American Association for the History of Medicine AAHM 2011 Annual Meeting Sheraton Society Hill Hotel, Philadelphia, PA April 28-May 1, 2011 Table of Contents CME Information …………………………………………………………………………………...…...........2 Acknowledgements…………………………………………………………………………………...…..........3 AAHM Program Sessions ………………………………………………………………………………....4-12 Affiliated Societies‘ Schedules …………………………………………………………………………....13-18 AAHM Officers ………………………………………………………………………………………...........19 AAHM Council ……………………………………………………………………………………................19 2011 Meeting Committee …………………………………………………………………………….............19 Maps …………………………………………………………………………………………………......20-22 Advertisements ………………………………………………………………………………………......23-26 Abstracts ………………………………………………………………………………………………..27-151 Notes ………………………………………………………………………………………………….152-156 Future AAHM Meeting Sites ………………………………………………………………………….........157 Conference Hotel Sheraton Society Hill 1 Dock Street Philadelphia, PA 19106 (215) 238-6000 Other Locations The Fielding H. Garrison Lecture and Reception will be held at the National Constitution Center 525 Arch Street Philadelphia, PA 19106 (215) 409-6600 Registration Book Exhibit (Foyer BCD) (Hamilton Room) Thursday, April 28, 12:00 PM-7:00 PM Thursday, April 28, 6:30 PM-9:00 PM Friday, April 29, 7:00 AM-5:00 PM Friday, April 29, 9:00 AM-5:30 PM Saturday, April 30, 7:00 AM-5:00 PM Saturday, April 30, 9:00 AM-6:00 PM Sunday, May 1, 9:00 AM-12:00 PM Cover Image: DR. MCMUNN‘S KINATE OF QUININE AND CINCHONINE, C. 1862–67 ANONYMOUS (AMERICAN, ACTIVE MID-1860S); PRINTED COURTESY OF THE WILLIAM H. HELFAND COLLECTION, PHILADELPHIA MUSEUM OF ART 84th Annual Meeting of the American Association for the History of Medicine Conference Abstract & Program Book April 28 - May 1, 2011 Sheraton Society Hill Hotel Philadelphia, PA Continuing Education Credit Information CONTINUING MEDICAL EDUCATION CREDITS Continuing medical education credit for the AAHM meeting will be offered by, The School of Medicine, State University of New York at Stony Brook.
    [Show full text]
  • Special Article a History of Pediatric Specialties
    0031-3998/03/5501-0163 PEDIATRIC RESEARCH Vol. 55, No. 1, 2004 Copyright © 2003 International Pediatric Research Foundation, Inc. Printed in U.S.A. SPECIAL ARTICLE A HISTORY OF PEDIATRIC SPECIALTIES This is the eighth article in our series on the history of pediatric specialties. Dr. Shulman describes the history of infectious diseases over the centuries. Many of these major killers of children were conquered by research that led to understanding the causes of these diseases and eventually to establishing means of prevention and treatment. Dr. Shulman also describes the organizations and publications that have furthered the development of treatment, research and education in this specialty. The future of this field includes the challenges of understanding and treating infectious diseases in immunocompromised children and in developing countries where infectious disease is still a major killer. The History of Pediatric Infectious Diseases STANFORD T. SHULMAN Northwestern University, The Feinberg School of Medicine, Division of Infectious Diseases, The Children’s Memorial Hospital, Chicago, IL 60614 U.S.A. ABSTRACT The history of Pediatric Infectious Diseases closely parallels (1933) all contributed to the evolution of the discipline of the history of Pediatrics at least until the last century, because Pediatric Infectious Disease, and numerous leaders of these historically infections comprised the major causes of childhood organizations had significant infectious diseases interests. The morbidity and mortality, as they still do in the developing
    [Show full text]
  • Presentation of the Howland Award to Horace Louis Hodes, M.D
    Pediatr. Res. 16: 917-919 (1982) Presentation of the Howland Award to Horace Louis Hodes, M.D. KURT HIRSCHHORN Department ofPediatrics, Mt. Sinai School ofMedicine, New York, New York, USA Dr. Hodes was born in Philadelphia on December 21, 1907. He mental epidemiology served him well in his life-long studies of received his elementary and high school education in Philadelphia clinical and experimental biology. After his return to Johns Hop­ and pursued one of his favorite activities by being a member of kins as Director of the Sydenham Hospital in Baltimore, he again his high school baseball team. During his childhood he had a left for several years during the war when he became a Lieutenant major experience which did much to lead to his determination to Commander in the navy as a member of the Rockefeller Naval study medicine and particularly pediatrics. When he was six years Research Unit and eventually as the officer in charge of the virus old, two of his younger brothers contracted diphtheria. The diag­ laboratory of the U.S. Naval Medical Research Unit in Guam. nosis was not made for a number of days so that they did not His four years in this Unit were highly fruitful in terms of receive antitoxin until the fifth day of illness, at which time they concentrated and important research and profoundly influenced were taken to the only contagious disease ward in Philadelphia at his continued commitment to experimental and clinical virology. the municipal hospital. They were intubated, survived for 25-30 After his tenure in the Navy, Dr.
    [Show full text]
  • A£ES==Z : F- /7-Lr /^Signature of Certifying Official/Title Date State Or Federal Agency and Bureau
    NPS Form 1M0O (J_v. 11/90) OMB No. 1002+O01I United States Department of the Interior National Park Service NATIONAL REGISTER OF HISTORIC PLACES REGISTRATION FORM This form is for use in nominating or requesting determinations for individual properties or districts. See instructions in How to Complete the National Register of Historic Places Registration Form (National Register Bulletin 16A). Complete each item by marking "x" in the appropriate box or by entering the information requested. If an item does not apply to the property being documented, enter "N/A" for "not applicable." For functions, architectural classification, materials, and areas of significance, enter only categories and subcategories from the instructions. Place additional entries and narrative items on continuation sheets (NPS Form 10-900a). Use a typewriter, word processor, or computer, to complete all items. 1. Name of Property Historic name: The Sydenham Hospital for Communicable Diseases Other names/site number: Montebello State Hospital (Preferred) B— l-fS^f t-f 2. Location Street & Number: Argonne Drive fN/Al Not for Publication City or town: Baltimore fN/A1 Vicinity State: Maryland Code: MP County: Baltimore (City) Code: 510 Zip Code: 21218 3. State/Federal Agency Certification ^__ As the designated authority under the National Historic Preservation Act, as amended, 1 hereby certify that this $4 nomination [ ] request for determination of eligibility meets the documentation standards for registering properties in the National Register of Historic Places and meets the procedural and professional requirements set forth in 36 CFR Part 60. In my opinion, the property ^ meets [ ] does not. meet the National Register criteria.
    [Show full text]
  • ACIP Recommendation 417 Smallpox Vaccine International Notes 425 Fatal Mumps Myocarditis — England
    CENTER FOR DISEASE CONTROL September 5, 1980 / Vol. 29 / No. 35 ACIP Recommendation 417 Smallpox Vaccine International Notes 425 Fatal Mumps Myocarditis — England MORBIDITY AND MORTALITY WEEKLY REPORT Recommendation of the Immunization Practices Advisory Committee (ACIP) Smallpox Vaccine ^ £QC LIBRARY, " f \ These revised A C IP recommendations on smallpox vaccine ackri'à\h/feâgef tO^Wccessfui eradication of smallpox from the world. s m a l l p o x v a c c i n e Smallpox vaccine (vaccinia virus) is a highly effective immunizing agent against small­ pox. The judicious use of smallpox vaccine has eradicated smallpox. A t the World Health Assembly in May 1980, the World Health Organization (WHO) declared the world free of smallpox. Smallpox vaccination of civilians is now indicated only for laboratory workers directly involved with smallpox or closely related orthopox viruses (e.g., monkeypox, vaccinia, and others). M is u s e o f s m a l l p o x v a c c i n e There is no evidence that smallpox vaccination has therapeutic value in the treatment °f recurrent herpes simplex infection, warts, or any other disease. Smallpox vaccine should never be used therapeutically. s m a l l p o x vaccination f o r international t r a v e l The United States and most other nations do not require proof of smallpox vaccina­ tion as a condition of entry. As of August 15, 1980, only 4 nations in Africa and Asia- Democratic Kampuchea (Cambodia), Madagascar, Djibouti, and Chad—continued to require an up-to-date certification of smallpox vaccination as a condition of entry even though medical reasons for this requirement no longer exist.
    [Show full text]
  • Immunization Against Infectious Disease 1968
    NCDC immunization against infectious disease 1968 U.S. DEPARTMENT OF HEALTH. EDUCATION, AND WELFARE PUBLIC HEALTH SERVICE ' HealtLServices and Mental Health Administration YJ, >S i National Communicable Disease Center - Atlanta, Georgia 30333 National Communicable Disease Center Library Atlanta, Georgia 30333 Contents Page FOREWORD .................................................................................... 1 INTRODUCTION ........................................................................... 2 CURRENT REVIEWS-SELECTED INFECTIOUS DISEASES 3 Diphtheria................................................................. 5 Tetanus.................................................................... 8 Pertussis (Whooping Cough) .................................. 10 Measles (Rubeola)................................................. 12 Mumps ...................................................................... 17 'Poliomyelitis ............................................................ 20 Rubella (German M easles).................................... 26 C holera ................................................................... 29 Viral Hepatitis......................................................... 30 Influenza................................................................. 32 Plague.............................................................. .. 34 R abies.................................................................... 36 Smallpox............................................ , .................... 40 Tuberculosis...........................................................
    [Show full text]
  • 19750308 Tape2.Pdf
    , , • -. "'. I' ,:\ " --~~--~-------~~~-~~-~-~-~~---~~-~-----'-"-'-jJ Jo, 1. Dr. Albert Sabin March 8,. 1975 Charleston I. Side A Q The interesting things of a relations between someone who runs a laboratory and a person who works with him is Dr. Oletsky's I" role in the first important scientific award you received, namely the Theobald Smith Award. It is an indication of ~hat Oletsky thought of you and it's also an indication of what scientists at the time thought of you, by making this award. The letters that I'; I have found indicate that Oletsky played a key role in recommending 1 - you for this award. A What's the question? Q The question is, how indicative is this of Oletsky's I' ,:.i relationship with the people he worked with? A I must perhaps limit, in myself, as to the award, I I:' frankiy didn't know that Oletsky recommended me. It's an indication of his selflessness~ In other words, he did it because of a very special kind of gentle personality. He never once did he let on, although after the award had been announced, and it's not such a terribly important award. It was an award for a contributions that a young man, and I introduced a.new concept of coristitutional barriers to'progressions of viruses in .'~. '. the nervous system, etc. It is a reflection of the way Oletsky '- " . operated, which on the one hand was very wonderful and on the " tb~r other hand, some of the people who worked with him found ~. I,", he was a very shy, retiring person, a very considerate person 1 ' " and, I would say perhaps my greatest debt to him was to leave me alone, and to give me support in what I wanted to do • .
    [Show full text]
  • Transcript of Horace L. Hodes, MD
    Call #: INT 0022 Title: Interview with Horace L. Hodes, MD by Albert S. Lyons, MD Date: October 9, 1974 Copyright: Icahn School of Medicine at Mount Sinai The Arthur H. Aufses, Jr. MD Archives This document is a transcript of an oral history interview from the collections of The Arthur H. Aufses, Jr. MD Archives. This material is provided to users in order to facilitate research and lessen wear on the original documents. It is made available solely for the personal use of individual researchers. Copies may not be transferred to another individual or organization, deposited at another institution, or reduplicated without prior written permission of the Aufses Archives. Provision of these archival materials in no way transfers either copyright or property right, nor does it constitute permission to publish in excess of "fair use" or to display materials. For questions concerning this document, please contact the Aufses Archives: The Arthur H. Aufses, Jr. MD Archives Box 1102 One Gustave L. Levy Place New York, NY 10029-6574 (212) 241-7239 [email protected] INT 0022 HODES 2 INT 0022 Mount Sinai Archives Interview with Horace L. Hodes, MD by Albert S. Lyons, MD October 9, 1974 LYONS: This is October 9, 1974. I’m now interviewing Dr. Horace Hodes in his office in the Annenberg Building on the 17th floor. Horace, when did you first come to Mount Sinai? HODES: I came here on July 1, 1949. I’d never been in this hospital up until about two months before that date. The way I happened to come here was the following.
    [Show full text]